Drug Type Autologous CAR-T |
Synonyms Anti CD19 U-CAR-T cell therapy, CD19-F-CAR-T, FAST CAR-19 + [4] |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 1 | CN | 21 Nov 2020 | |
CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | CN | 17 Jan 2019 |
Phase 1 | 16 | oqifdnngxn(wrqpepadkp) = In comparison to the high dose group, patients administered low to middle dose levels experienced mild adverse events. Across 14 patients in the low to mid doses group, only 2 (14%) Grade 3 CRS and 1 (7%) manageable Grade 3 ICANS were reported; while in the 4 patients of the high dose group, there were 3 (75%) Grade 3 CRS and 2 (50%) Grade 1-2 ICANS. ubtuhazclb (myoggshagb ) | Positive | 21 Jun 2019 |